| Literature DB >> 26442901 |
Kavithalakshmi Sataranatarajan1, Yuji Ikeno2, Alex Bokov3, Denis Feliers1, Himabindu Yalamanchili1, Hak Joo Lee1, Meenalakshmi M Mariappan1, Hooman Tabatabai-Mir1, Vivian Diaz4, Sanjay Prasad1, Martin A Javors1, Goutam Ghosh Choudhury5, Gene B Hubbard6, Jeffrey L Barnes1, Arlan Richardson7, Balakuntalam S Kasinath8.
Abstract
We examined the effect of rapamycin on the life span of a mouse model of type 2 diabetes, db/db mice. At 4 months of age, male and female C57BLKSJ-lepr (db/db) mice (db/db) were placed on either a control diet, lacking rapamycin or a diet containing rapamycin and maintained on these diets over their life span. Rapamycin was found to reduce the life span of the db/db mice. The median survival of male db/db mice fed the control and rapamycin diets was 349 and 302 days, respectively, and the median survival of female db/db mice fed the control and rapamycin diets was 487 and 411 days, respectively. Adjusting for gender differences, rapamycin increased the mortality risk 1.7-fold in both male and female db/db mice. End-of-life pathological data showed that suppurative inflammation was the main cause of death in the db/db mice, which is enhanced slightly by rapamycin treatment.Entities:
Keywords: Life span; Obesity; Toxicity; mTOR Inhibition
Mesh:
Substances:
Year: 2015 PMID: 26442901 PMCID: PMC4906320 DOI: 10.1093/gerona/glv170
Source DB: PubMed Journal: J Gerontol A Biol Sci Med Sci ISSN: 1079-5006 Impact factor: 6.053